Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer

Medical Science Monitor

Volumn 17, Issue 12, 2011, Pages

  Rybárová, Silvia ^a   Vecanová, Janka ^a   Hodorová, Ingrid ^a   Mihalik, Jozef ^a   Čižmáriková, Martina ^a   Mojžiš, Ján ^a   Solár, Peter ^a   Benický, Marián ^b   Adamkov, Marian ^c   Mirossay, Ladislav ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b FACULTY HOSPITAL   (Slovakia)

^c University Teaching Hospital in Martin   (Slovakia)

Author keywords

Breast cancer; MDR1; p53; Polymorphisms; XRCC1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE RECEPTOR; PROTEIN P53; XRCC1 PROTEIN;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 82755188144     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882121     Document Type: Article

References (66)

1. Jemal A, Thomas A, Murray T et al: Cancer statistics. CA Cancer J Clin, 2002; 52: 23-47
2. Lamerdin J, Montegomery M, Stilwagen S et al: Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics, 1995; 25: 547-54
3. Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exit at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 1998; 58: 604-8
4. Helzlsouer KJ, Harris EL, Parshad R et al: DNA repair proficiency: potential susceptibility factor for breast cancer. J Natl Cancer Inst, 1996; 88: 754-55
5. Thompson LH, West MG: XRCC1 keeps DNA from getting stranded. Mutat Res, 2000; 459: 1-18
6. Greenblatt MS, Bennet WP, Hollstein M et al: Mutation of p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994; 54: 4855-78
7. Gayet L, Dayan G, Barakat S et al: Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry, 2005; 44: 4499-509
8. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst, 1997; 2: 917-31
9. Chung HC, Rha SY, Kim JH et al: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat, 1997; 42: 65-72
10. Sobin LH, Wittekind C: TNM classification of malignant tumours. 5. New York: Wiley-Liss Inc., 2002
11. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991; 19: 403-10
12. Dufloth RM, Arruda A, Heinrich JKR et al: The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer. Gen Mol Res, 2008; 7: 574-82
13. Costa S, Pinto D, Pereira D et al: XRCC1 Arg399Gln and RAD53 5'UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients. Breast Cancer Res Treat, 2008; 109: 183-85
14. Qu T, Morii E, Oboki K et al: Micronuclei in EM9 cells expressing polymorphic forms of human XRCC1. Cancer Lett, 2005; 221: 91-95
15. Sutherland BM, Bennet PV, Sutherland JC et al: Clustered DNA damages induced by x rays in human cells. Radiat Res, 2002; 157: 611-16
16. Ward JF: Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res, 1995; 142: 362-68
17. de Jong MM, Nolte IM, te Meerman GJ et al: Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet, 2002; 39: 225-42
18. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nature Reviews Cancer, 2002; 2: 594-604
19. Borresen-Dale AL: TP53 and breast cancer. Hum Mutat, 2003; 21: 292-300
20. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer, 2006; 13: 293-325
21. Baumbusch LO, Myhre S, Langerod A et al: Expression of full-lenght p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer, 2006; 5: 47
22. Friedlander P, Haupt Y, Prives C: A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Molecular and Cellular Biology, 1996; 16: 4961-71
23. Montero S, Guzman C, Vargas C et al: Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol, 2001; 22: 337-44
24. Tsutsui S, Ohno S, Murakam S: Prognostic value of p53 protein expression in breast cancer, an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer, 2001; 8: 194-201
25. Menard S, Fortis S, Castiglioni F et al: Her2 as a prognostic factor in breast cancer. Oncology, 2001; 61: 67-72
26. Korkolis D, Ardavanis A, Yotis J et al: Her2/neu overexpression in breast cancer: an immunohistochemical study including correlation with clinicopathologic parameters, p53 oncoprotein and cathepsin-D. Anticancer Res, 2001; 21: 2207-12
27. Chariyalertsak S, Chariyalertsak S, Cheirsilpa A et al: Prognostic importace of p53 and c-erbB-2 oncoproteins overexpression in patiens with breast cancer. J Med Assoc Tha, 1998; 81: 698-704
28. Erdem O, Dorsun A, Coşkun U et al: The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori, 2005; 91: 46-52
29. de Roos MA, de Bock GH, de Vries J et al: p53 overexpression is a predictor of local reccurence after treatment for both in situ and invasive ductal carcinoma of the breast. Surg Res, 2007; 140: 109-14
30. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002; 2: 48-58
31. Linn SC, Giaccone G, van Diest PJ et al: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Oncol, 1995; 6: 697-85
32. Rybarova S, Hodorova I, Hajdukova M et al: Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma, 2006; 53: 128-35
33. Rudas M, Filipits M, Taucher S et al: Expression of MRP1, LRP and Pgp in breast carcinoma treated with preoperative chemotherapy. Breast Cancer Res Treat, 2003; 81: 149-57
34. Li EX, Li Y, Yang J et al: Influence of P-glycoprotein expression on chemotherapeutic response of metastatic breast carcinoma. Ai Zheng, 2002; 21: 430-32
35. Faneyte IF, Kristel PM, van de Vijver MJ: Multidrug resistence associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res, 2004; 24: 2931-39
36. Yu P, Xiao NX, Chen YP: Expression of P-glycoprotein and lung resistence protein in brest carcinoma and its relationship with prognosis. Ai Zheng, 2003; 22: 1339-42
37. Turgut S, Yaren A, Kursunluoglu R et al: MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res, 2007; 38: 539-44
38. Rothman N, Wacholder S, Caporaso NE et al: The use of common genetic polymorphisms enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta, 2001; 1471: C1-10
39. Hosseini M, Houshmand M, Ebrahimi A: MTHFR polymorphisms and breast cancer risk. Arch Med Sci, 2011; 1: 134-37
40. Jabłonowska E, Kołacinska A, Kuydowicz J et al: Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients. Arch Med Sci, 2010; 6: 860-65
41. Yildiz Y, YaylIm-Eraltan I, Arikan S et al: Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer? Arch Med Sci, 2010; 6: 932-36
42. Duell EJ, Millikan RC, Pittman GS et al: Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev, 2001; 10: 217-22
43. Sterpone S, Mastellone V, Padua L et al: Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women. J Cancer Res Clin Oncol, 2010; 4: 631-36
44. Saadat M: Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat, 2010; 124(3): 785-91
45. Duell EJ, Millikan RC, Pittman GS et al: Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev, 2001; 10: 217-22
46. Nexo BA, Vogel U, Olsen A et al: A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis, 2003; 24: 899-904
47. Shen J, Gammon MD, Terry MB et al: Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2005; 14: 336-42
48. Moullan N, Cox DG, Angele S et al: Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev, 2003; 12: 1168-74
49. Wang Y, Spitz MR, Zhu Y: From genotype to phenotype: correlatin XRCC1 polymorphisms with mutagen transporter. DNA Repair (Amst.), 2003; 2: 901-8
50. Lunn RM, Langlois RG, Hsieh LL et al: Xrcc1 polymorphisms: effects on aflatoxin b1-dna adducts and glycophorin a variant frequency. Cancer Res, 1999; 59: 2557-61
51. Matullo G, Guarrera S, Carturan S et al: DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer, 2001; 92: 562-67
52. Abdel-Rahman SZ, Soliman AS, Bondy ML et al: Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett, 2000; 159: 79-86
53. Duell EJ, Wiencke JK, Cheng TJ et al: Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damag in human blood mononuclear cells. Carcinogenesis, 2000; 21: 965-71
54. Hu JJ, Smith TR, Miller MS et al: Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen, 2002; 39: 208-15
55. Cheng XD, Lu WG, Ye F et al: The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res, 2009; 28: 91
56. Beckman G, Birgander R, Sjalander A et al: Is p53 polymorphism maintained by natural selection? Hum Hered, 1994; 44: 266-70
57. Kara N, Karakus N, Ulusoy AN et al: P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol, 2010; 29: 387-92
58. Bisof V, Salihovic MP, Narancic NS et al: TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol, 2010; 31: 539-44
59. Akkiprik M, Sonmez O, Gulluoglu BM et al: Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res, 2009; 15: 359-68
60. Dumont P, Leu JI, Della Pietra AC et al: The codon 72 polymorphic variant of p53 have markedly different apoptotic potential. Nat Genet, 2003; 33: 357-65
61. Hoffmeyer S, Burk O, von Richter O et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci, USA 2000; 97: 3473-78
62. Kimchi-Sarfaty Ch, Oh JM, Kim IW et al: A"silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 2007; 315: 525-28
63. Čižmarikova M, Wagnerova M, Schonova L et al: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J, 2009; 10: 62-69
64. Owen A, Goldring C, Morgan P et al: Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol, 2005; 59: 365-70
65. Siegmund W, Ludwig K, Giessmann T et al: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther, 2002; 72: 572-83
66. Yoshikawa T, Kanazawa H, Tanaka J et al: Gene polymorphism of epidermal growth factor receptor and airway hyperresponsiveness in young allergic subjects without respiratory symptoms. Med Sci Monit, 2010; 16(4) CR163-71